Abstract
Background: Hemorrhagic transformation (HT) is a complication that occurs spontaneously or after thrombolysis in acute ischemic stroke (AIS) and can increase morbidity and mortality. The association of biomarkers with the risk of HT has been variably reported. We conducted a systematic review of the literature and meta-analysis and sought to compare blood biomarkers associated with HT and its subtypes by evaluating its predictability and correlation with outcome in AIS. Methods: The study protocol was registered in the PROSPERO database (CRD42020201334) and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Among 2,230 articles identified from Cochrane Library, PubMed, and Web of Science databases, 30 quality-appraised articles were found eligible. Meta-analysis was conducted for matrix metalloproteinase-9 (MMP-9), cellular fibronectin (c-Fn), ferritin, S100 calcium-binding protein B (S100B), and neutrophil-lymphocyte ratio (NLR). We also reviewed biomarkers for correlation with the functional outcome at 90 days from stroke onset (poor outcome modified Rankin scale >2). Results: The pooled diagnostic odds ratio (DORpooled) was the highest for baseline c-Fn levels (299.253 [95% CI, 20.508–4,366.709]), followed by MMP-9 (DORpooled, 29.571 [95% CI 17.750–49.267]) and ferritin (DORpooled, 24.032 [95% CI 2.557–225.871]). However, wide confidence intervals for ferritin and c-Fn suggested lesser reliability of the markers. Patients with MMP-9 levels ≥140 ng/mL were 29.5 times at higher risk of developing symptomatic HT after AIS (area under the curve = 0.881). S100B (DORpooled, 6.286 [95% CI, 1.861–21.230]) and NLR (DORpooled, 5.036 [95% CI, 2.898–8.749]) had lower diagnostic accuracies. Among the markers not included for meta-analysis, caveolin-1, thrombin-activated fibrinolysis inhibitor, plasminogen activator inhibitor-1, and soluble ST2 were highly sensitive. Elevated levels of MMP-9, ferritin, and NLR were found to be associated with poor functional outcomes and mortality. Conclusion: Of the 5 biomarkers, there was enough evidence that MMP-9 has higher diagnostic accuracy for predicting the risk of HT before thrombolysis. MMP-9, ferritin, and NLR also predicted poor short-term outcomes.
References
1.
Yaghi
S
, Willey
JZ
, Cucchiara
B
, Goldstein
JN
, Gonzales
NR
, Khatri
P
, Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic atroke: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association
. Stroke
. 2017 Dec
;48
(12
):e343
–61
. .2.
Diedler
J
, Ahmed
N
, Sykora
M
, Uyttenboogaart
M
, Overgaard
K
, Luijckx
GJ
, Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset
. Stroke
. 2010 Feb
;41
(2
):288
–94
. .3.
Khatri
P
, Wechsler
LR
, Broderick
JP
. Intracranial hemorrhage associated with revascularization therapies
. Stroke
. 2007 Feb
;38
(2
):431
–40
. .4.
de Andrade
JBC
, Mohr
JP
, Lima
FO
, Carvalho
JJF
, de Farias
VAE
, Oliveira-Filho
J
, Predicting hemorrhagic transformation in patients not submitted to reperfusion therapies
. J Stroke Cerebrovasc Dis
. 2020 Aug
;29
(8
):104940
. .5.
Álvarez-Sabín
J
, Maisterra
O
, Santamarina
E
, Kase
CS
. Factors influencing haemorrhagic transformation in ischaemic stroke
. Lancet Neurol
. 2013 Jul
;12
(7
):689
–705
. .6.
Jensen
M
, Schlemm
E
, Cheng
B
, Lettow
I
, Quandt
F
, Boutitie
F
, Clinical characteristics and outcome of patients with hemorrhagic transformation after intravenous thrombolysis in the WAKE-UP trial
. Front Neurol
. 2020 Aug 28
;11
:957
. .7.
Arba
F
, Rinaldi
C
, Caimano
D
, Vit
F
, Busto
G
, Fainardi
E
. Blood-brain barrier disruption and hemorrhagic transformation in acute ischemic stroke: systematic review and meta-analysis
. Front Neurol
. 2020 Jan 21
;11
:594613
. .8.
Jickling
GC
, Liu
D
, Stamova
B
, Ander
BP
, Zhan
X
, Lu
A
, Hemorrhagic transformation after ischemic stroke in animals and humans
. J Cereb Blood Flow Metab
. 2014 Feb
;34
(2
):185
–99
. .9.
Paciaroni
M
, Agnelli
G
, Corea
F
, Ageno
W
, Alberti
A
, Lanari
A
, Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study
. Stroke
. 2008 Aug
;39
(8
):2249
–56
. .10.
Jickling
GC
, Manolescu
BN
. Breaking down barriers to identify hemorrhagic transformation in ischemic stroke
. Neurology
. 2012 Oct 16
;79
(16
):1632
–3
. .11.
Moher
D
, Liberati
A
, Tetzlaff
J
, Altman
DG
; Prisma Group
. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
. BMJ
. 2009 Jul 21
;339
(7
):b2535
. .12.
Andrade
JBC
, Mohr
JP
, Lima
FO
, de Carvalho
JJF
, Barros
LCM
, Nepomuceno
CR
, The role of hemorrhagic transformation in acute ischemic stroke upon clinical complications and outcomes
. J Stroke Cerebrovasc Dis
. 2020 Aug
;29
(8
):104898
. .13.
Berger
C
, Fiorelli
M
, Steiner
T
, Schäbitz
WR
, Bozzao
L
, Bluhmki
E
, Hemorrhagic transformation of ischemic brain tissue: asymptomatic or symptomatic?
Stroke
. 2001 Jun
;32
(6
):1330
–5
. .14.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
. Tissue plasminogen activator for acute ischemic stroke
. N Engl J Med
. 1995 Dec 14
;333
(24
):1581
–7
. .15.
Whiting
PF
, Weswood
ME
, Rutjes
AW
, Reitsma
JB
, Bossuyt
PN
, Kleijnen
J
. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies
. BMC Med Res Methodol
. 2006 Mar 6
;6
:9
. .16.
Bristol Medical School: Population Health Sciences University of Bristol [Internet]. Bristol: QUADAS-2. [cited 2020 Jun 7]. https://www.bristol.ac.uk/population-health-sciences/projects/quadas/quadas-2.
17.
Von Elm
E
, Altman
DG
, Egger
M
, Pocock
SJ
, Gøtzsche
PC
, Vandenbroucke
JP
, The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
. Int J Surg
. 2014 Dec 1
;12
(12
):1495
–9
. .18.
Adams
HP
Jr, Bendixen
BH
, Kappelle
LJ
, Biller
J
, Love
BB
, Gordon
DL
, Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment
. Stroke
. 1993 Jan
;24
(1
):35
–41
. .19.
Castellanos
M
, Leira
R
, Serena
J
, Pumar
JM
, Lizasoain
I
, Castillo
J
, Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke
. Stroke
. 2003 Jan
;34
(1
):40
–6
. .20.
Yuan
R
, Tan
S
, Wang
D
, Wu
S
, Cao
X
, Zhang
S
, Predictive value of plasma matrix metalloproteinase-9 concentrations for spontaneous haemorrhagic transformation in patients with acute ischaemic stroke: a cohort study in Chinese patients
. J Clin Neurosci
. 2018 Dec
;58
:108
–12
. .21.
Montaner
J
, Alvarez-Sabín
J
, Molina
CA
, Anglés
A
, Abilleira
S
, Arenillas
J
, Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke
. Stroke
. 2001 Dec 1
;32
(12
):2762
–7
. .22.
Kazmierski
R
, Michalak
S
, Wencel-Warot
A
, Nowinski
WL
. Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients
. Neurology
. 2012 Oct 16
;79
(16
):1677
–85
. .23.
Hernandez-Guillamon
M
, Garcia-Bonilla
L
, Solé
M
, Sosti
V
, Parés
M
, Campos
M
, Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke
. Stroke
. 2010 Jul
;41
(7
):1528
–35
. .24.
Castellanos
M
, Sobrino
T
, Millán
M
, García
M
, Arenillas
J
, Nombela
F
, Serum cellular fibronectin and matrix metalloproteinase-9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke: a multicenter confirmatory study
. Stroke
. 2007 Jun
;38
(6
):1855
–9
. .25.
Castellanos
M
, Leira
R
, Serena
J
, Blanco
M
, Pedraza
S
, Castillo
J
, Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke
. Stroke
. 2004 Jul
;35
(7
):1671
–6
. .26.
Choi
KH
, Park
MS
, Kim
JT
, Nam
TS
, Choi
SM
, Kim
BC
, The serum ferritin level is an important predictor of hemorrhagic transformation in acute ischaemic stroke
. Eur J Neurol
. 2012 Apr
;19
(4
):570
–7
. .27.
Millán
M
, Sobrino
T
, Arenillas
JF
, Rodríguez-Yáñez
M
, García
M
, Nombela
F
, Biological signatures of brain damage associated with high serum ferritin levels in patients with acute ischemic stroke and thrombolytic treatment
. Dis Markers
. 2008
;25
(3
):181
–8
. .28.
Montaner
J
, Molina
CA
, Monasterio
J
, Abilleira
S
, Arenillas
JF
, Ribó
M
, Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke
. Circulation
. 2003 Feb 4
;107
(4
):598
–603
. .29.
Navarro-Sobrino
M
, Rosell
A
, Hernández-Guillamon
M
, Penalba
A
, Boada
C
, Domingues-Montanari
S
, A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke
. Atherosclerosis
. 2011 May
;216
(1
):205
–11
. .30.
Wolcott
Z
, Batra
A
, Bevers
MB
, Sastre
C
, Khoury
J
, Sperling
M
, Soluble ST2 predicts outcome and hemorrhagic transformation after acute stroke
. Ann Clin Transl Neurol
. 2017 Jul 5
;4
(8
):553
–63
. .31.
Ribo
M
, Montaner
J
, Molina
CA
, Arenillas
JF
, Santamarina
E
, Quintana
M
, Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator
. Stroke
. 2004 Sep
;35
(9
):2123
–7
. .32.
Mechtouff
L
, Bochaton
T
, Paccalet
A
, Crola Da Silva
C
, Buisson
M
, Amaz
C
, Matrix metalloproteinase-9 relationship with infarct growth and hemorrhagic transformation in the era of thrombectomy
. Front Neurol
. 2020 Jun 9
;11
:473
. .33.
Duan
Z
, Wang
H
, Wang
Z
, Hao
Y
, Zi
W
, Yang
D
, ; ACTUAL Investigators
. Neutrophil-lymphocyte ratio predicts functional and safety outcomes after endovascular treatment for acute ischemic stroke
. Cerebrovasc Dis
. 2018
;45
(5–6
):221
–7
.34.
Pikija
S
, Sztriha
LK
, Killer-Oberpfalzer
M
, Weymayr
F
, Hecker
C
, Ramesmayer
C
, Neutrophil to lymphocyte ratio predicts intracranial hemorrhage after endovascular thrombectomy in acute ischemic stroke
. J Neuroinflammation
. 2018 Nov 15
;15
(1
):319
. .35.
Matosevic
B
, Knoflach
M
, Werner
P
, Pechlaner
R
, Zangerle
A
, Ruecker
M
, Fibrinogen degradation coagulopathy and bleeding complications after stroke thrombolysis
. Neurology
. 2013 Mar 26
;80
(13
):1216
–24
. .36.
Foerch
C
, Wunderlich
MT
, Dvorak
F
, Humpich
M
, Kahles
T
, Goertler
M
, Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke
. Stroke
. 2007 Sep
;38
(9
):2491
–5
. .37.
Che
R
, Huang
X
, Zhao
W
, Jiang
F
, Wu
L
, Zhang
Z
, Low serum albumin level as a predictor of hemorrhage transformation after intravenous thrombolysis in ischemic stroke patients
. Sci Rep
. 2017 Aug 10
;7
(1
):7776
. .38.
Świtońska
M
, Piekuś-Słomka
N
, Słomka
A
, Sokal
P
, Żekanowska
E
, Lattanzi
S
. Neutrophil-to-lymphocyte ratio and symptomatic hemorrhagic transformation in ischemic stroke patients undergoing revascularization
. Brain Sci
. 2020 Oct 23
;10
(11
):771
.39.
Lin
SF
, Chao
AC
, Hu
HH
, Lin
RT
, Chen
CH
, Chan
L
, ; Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group
. Low cholesterol levels increase symptomatic intracranial hemorrhage rates after intravenous thrombolysis: a multicenter cohort validation study
. J Atheroscler Thromb
. 2019 Jun 1
;26
(6
):513
–27
.40.
El-Banhawy
E
, Amer
H
, Younes
K
, Nada
MA
, Helmy
H
, Hassan
MI
. Plasma matrix metalloproteinase-9 (MMP-9) and hemorrhagic transformation in acute ischemic stroke
. Egypt J Neurol Psychiat Neurosurg
. 2014 Apr 1
;51
:159
–66
.41.
Malhotra
K
, Goyal
N
, Chang
JJ
, Broce
M
, Pandhi
A
, Kerro
A
, Differential leukocyte counts on admission predict outcomes in patients with acute ischaemic stroke treated with intravenous thrombolysis
. Eur J Neurol
. 2018 Dec
;25
(12
):1417
–24
. .42.
Molnar
T
, Borocz
K
, Berki
T
, Szapary
L
, Szolics
A
, Janszky
J
, Subacute elevation of plasma level of caspase-cleaved cytokeratin-18 is associated with hemorrhagic transformation and functional outcome in ischemic stroke
. J Stroke Cerebrovasc Dis
. 2019 Mar
;28
(3
):719
–27
. .43.
Xing
Y
, Guo
ZN
, Yan
S
, Jin
H
, Wang
S
, Yang
Y
. Increased globulin and its association with hemorrhagic transformation in patients receiving intra-arterial thrombolysis therapy
. Neurosci Bull
. 2014 Jun
;30
(3
):469
–76
. .44.
Maestrini
I
, Strbian
D
, Gautier
S
, Haapaniemi
E
, Moulin
S
, Sairanen
T
, Higher neutrophil counts before thrombolysis for cerebral ischemia predict worse outcomes
. Neurology
. 2015 Oct 20
;85
(16
):1408
–16
. .45.
Castellanos
M
, van Eendenburg
C
, Gubern
C
, Kádár
E
, Huguet
G
, Puig
J
, Low levels of caveolin-1 predict symptomatic bleeding after thrombolytic therapy in patients with acute ischemic stroke
. Stroke
. 2018 Jun
;49
(6
):1525
–7
. .46.
Jucevičiūtė
N
, Mikužis
P
, Balnytė
R
. Absolute blood eosinophil count could be a potential biomarker for predicting haemorrhagic transformation after intravenous thrombolysis for acute ischaemic stroke
. BMC Neurol
. 2019 Jun 13
;19
(1
):127
.47.
Guo
Z
, Yu
S
, Xiao
L
, Chen
X
, Ye
R
, Zheng
P
, Dynamic change of neutrophil to lymphocyte ratio and hemorrhagic transformation after thrombolysis in stroke
. J Neuroinflammation
. 2016 Aug 26
;13
(1
):199
. .48.
Goyal
N
, Tsivgoulis
G
, Chang
JJ
, Malhotra
K
, Pandhi
A
, Ishfaq
MF
, Admission neutrophil-to-lymphocyte ratio as a prognostic biomarker of outcomes in large vessel occlusion strokes
. Stroke
. 2018 Aug
;49
(8
):1985
–7
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
